Clinical Utility and Validation of the Krakow DCM Risk Score-A Prognostic Model Dedicated to Dilated Cardiomyopathy

• Published in: Journal of personalized medicine Vol. 12; no. 2; p. 236
• Main Authors: Dziewięcka, Ewa, Winiarczyk, Mateusz, Wiśniowska-Śmiałek, Sylwia, Karabinowska-Małocha, Aleksandra, Gliniak, Matylda, Robak, Jan, Kaciczak, Monika, Leszek, Przemysław, Celińska-Spodar, Małgorzata, Dziewięcki, Marcin, Rubiś, Paweł
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI AG 08.02.2022; MDPI
• Subjects: Accuracy; Age; Anemia; Cardiomyopathy; Cardiovascular disease; Congestive heart failure; Coronary vessels; Diabetes; Dilated cardiomyopathy; Heart; Kidney diseases; Medical imaging; Mortality; Normal distribution; Patients; Population studies; Precision medicine; Risk groups; Statistical analysis; Transplants & implants; Vein & artery diseases; Krakow DCM Risk Score; non-ischemic heart failure with reduced ejection fraction; prognostic model; prognosis; mortality risk; dilated cardiomyopathy
• ISSN: 2075-4426; 2075-4426
• DOI: 10.3390/jpm12020236

One of the most common causes of heart failure is dilated cardiomyopathy (DCM). In DCM, the mortality risk is high and reaches approximately 20% in 5 years. A patient's prognosis should be established for appropriate HF management. However, so far, no validated tools have been available for the DCM population. The study population consisted of 735 DCM patients: 406 from the derivation cohort (previously described) and 329 from the validation cohort (from 2009 to 2020, with outcome data after a mean of 42 months). For each DCM patient, the individual mortality risk was calculated based on the Krakow DCM Risk Score. During follow-up, 49 (15%) patients of the validation cohort died. They had shown significantly higher calculated 1-to-5-year mortality risks. The Krakow DCM Risk Score yielded good discrimination in terms of overall mortality risk, with an AUC of 0.704-0.765. Based on a 2-year mortality risk, patients were divided into non-high (≤6%) and high (>6%) mortality risk groups. The observed mortality rates were 8.3% ( = 44) vs. 42.6% ( = 75), respectively (HR 3.37; 95%CI 1.88-6.05; < 0.0001). The Krakow DCM Risk Score was found to have good predictive accuracy. The 2-year mortality risk > 6% has good discrimination for the identification of high-risk patients and can be applied in everyday practice.